These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
432 related articles for article (PubMed ID: 11181372)
1. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Petraitiene R; Petraitis V; Groll AH; Sein T; Piscitelli S; Candelario M; Field-Ridley A; Avila N; Bacher J; Walsh TJ Antimicrob Agents Chemother; 2001 Mar; 45(3):857-69. PubMed ID: 11181372 [TBL] [Abstract][Full Text] [Related]
2. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Petraitiene R; Petraitis V; Groll AH; Sein T; Schaufele RL; Francesconi A; Bacher J; Avila NA; Walsh TJ Antimicrob Agents Chemother; 2002 Jan; 46(1):12-23. PubMed ID: 11751105 [TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits. Petraitiene R; Petraitis V; Lyman CA; Groll AH; Mickiene D; Peter J; Bacher J; Roussillon K; Hemmings M; Armstrong D; Avila NA; Walsh TJ Antimicrob Agents Chemother; 2004 Apr; 48(4):1188-96. PubMed ID: 15047519 [TBL] [Abstract][Full Text] [Related]
4. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Petraitis V; Petraitiene R; Groll AH; Bell A; Callender DP; Sein T; Schaufele RL; McMillian CL; Bacher J; Walsh TJ Antimicrob Agents Chemother; 1998 Nov; 42(11):2898-905. PubMed ID: 9797223 [TBL] [Abstract][Full Text] [Related]
5. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Lewis RE; Prince RA; Chi J; Kontoyiannis DP Antimicrob Agents Chemother; 2002 Oct; 46(10):3208-14. PubMed ID: 12234846 [TBL] [Abstract][Full Text] [Related]
6. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Petraitis V; Petraitiene R; Groll AH; Roussillon K; Hemmings M; Lyman CA; Sein T; Bacher J; Bekersky I; Walsh TJ Antimicrob Agents Chemother; 2002 Jun; 46(6):1857-69. PubMed ID: 12019101 [TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Lewis RE; Liao G; Hou J; Chamilos G; Prince RA; Kontoyiannis DP Antimicrob Agents Chemother; 2007 Apr; 51(4):1253-8. PubMed ID: 17261624 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Oakley KL; Morrissey G; Denning DW Antimicrob Agents Chemother; 1997 Jul; 41(7):1504-7. PubMed ID: 9210674 [TBL] [Abstract][Full Text] [Related]
15. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. Walsh TJ; Petraitis V; Petraitiene R; Field-Ridley A; Sutton D; Ghannoum M; Sein T; Schaufele R; Peter J; Bacher J; Casler H; Armstrong D; Espinel-Ingroff A; Rinaldi MG; Lyman CA J Infect Dis; 2003 Jul; 188(2):305-19. PubMed ID: 12854088 [TBL] [Abstract][Full Text] [Related]
16. Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis. van Vianen W; de Marie S; ten Kate MT; Mathot RA; Bakker-Woudenberg IA J Antimicrob Chemother; 2006 Apr; 57(4):732-40. PubMed ID: 16464895 [TBL] [Abstract][Full Text] [Related]
17. Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits: efficacy, safety and non-compartmental pharmacokinetics. Groll AH; Gonzalez CE; Giri N; Kligys K; Love W; Peter J; Feuerstein E; Bacher J; Piscitelli SC; Walsh TJ J Antimicrob Chemother; 1999 Jan; 43(1):95-103. PubMed ID: 10381106 [TBL] [Abstract][Full Text] [Related]
18. Tissue distribution and antifungal effect of liposomal itraconazole in experimental cryptococcosis and pulmonary aspergillosis. Le Conte P; Joly V; Saint-Julien L; Gillardin JM; Carbon C; Yeni P Am Rev Respir Dis; 1992 Feb; 145(2 Pt 1):424-9. PubMed ID: 1310577 [TBL] [Abstract][Full Text] [Related]
19. Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. Roberts J; Schock K; Marino S; Andriole VT Antimicrob Agents Chemother; 2000 Dec; 44(12):3381-8. PubMed ID: 11083644 [TBL] [Abstract][Full Text] [Related]
20. Caspofungin prolongs survival of transiently neutropenic rats with advanced-stage invasive pulmonary aspergillosis. van de Sande WW; van Vianen W; ten Kate MT; Vissers J; Laurijsens J; Tavakol M; Rijnders BJ; Mathot RA; Bakker-Woudenberg IA Antimicrob Agents Chemother; 2008 Apr; 52(4):1345-50. PubMed ID: 18195059 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]